Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 44 of 58, showing 10 Applications out of 576 total, starting on record 431, ending on 440

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

431.

ECCT/21/06/05   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of ageand older   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR-PHRD THIKA PROJECT
 
02-08-2021 View

432.

ECCT/25/03/04   Ndovu RCT
    Investigating the optimal management of dolutegravir resistance: an open-label randomised controlled trial of maintaining dolutegravir or switch to ritonavir-boosted darunavir   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Kenyatta National Hospital (KNH) (Nairobi City county)
2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
3. Bomu Hospital (Mombasa county)
 
14-07-2025 View

433.

ECCT/23/03/01   Micronutrient supplementation
    Optimizing nutrient supplementation among pregnant and reproductive age women in Kenya (Virutubisho)   
Principal Investigator(s)
1. DR. Martha Kaeni Mwangome
Site(s) in Kenya
KILIFI
 
24-07-2023 View

434.

ECCT/22/11/02   UNCPM 22120 5-FU Study
    UNCPM  22120: Safety of adjuvant, self-administered intravaginal 5-fluorouracil (5-FU) cream following cervical intraepithelial neoplasia grade 2 and 3 (CIN2/3) treatment among HIV-positive women in Kenya: A pilot study   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
2. Chemtai Mungo
Site(s) in Kenya
Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH)
 
01-03-2023 View

435.

ECCT/25/11/06   MK-8527-011 Study
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis   
Principal Investigator(s)
1. Dr Maricianah Onono
Site(s) in Kenya
1. Nyanza Reproductive Health Society (NRHS), UNIM Research and Training Centre (URTC) (Kisumu county)
2. Kenya Impact Research and Development Organization (K-IRDO) (Kisumu county)
3. Partners for Health and Development in Africa – Sex workers Outreach Program (PHDA – SWOP) Clinic- Nairobi, Kenya (Nairobi City county)
 
05-03-2026 View

436.

ECCT/24/08/04   WHO A66045
    Heat-stable carbetocin for the treatment of postpartum haemorrhage: a phase III, randomized, double-blind, active controlled, multicountry, multicentre, non-inferiority trial   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
1. Machakos county hospital (Machakos county)
2. Pumwani maternity hospital (Nairobi City county)
3. Kiambu level 5 hospital (Kiambu county)
 
06-02-2025 View

437.

ECCT/10/09/03   A0661201
    A0661201   AN OPEN LABEL, NON-COMPARATIVE STUDY TO EVALUATE PARASITOLOGICAL CLEARANCE RATES AND PHARMACOKINETICS OF AZITHROMYCIN AND CHLOROQUINE FOLLOWING ADMINISTRATION OF A FIXED DOSE COMBINATION OF AZITHROMYCIN AND CHLOROQUINE (AZCQ) IN ASYMPTOMATIC PREGNANT WOMEN WITH PLASMODIUMFALCIPARUM PARASITEMIA IN SUB-SAHARAN AFRICA   
Principal Investigator(s)
1. Joshua Kimani
Site(s) in Kenya
University of Nairobi Institute of Tropical and Infectious Diseases Siaya District Hospital
 
25-09-2013 View

438.

ECCT/13/08/02   MalPaC Trial
    Comparing drug-regimens for clearing parasites in Phase IIb trial designs prior to PCR monitoring for Plasmodium falciparum infection.   
Principal Investigator(s)
1. Caroline Amolo Ogwang
2. Francis Maina Ndung\'u
Site(s) in Kenya
Junju
 
29-07-2013 View

439.

ECCT/24/03/03   DoxyDOT Study
    Weekly doxycycline DOT for STI prevention among cisgender women taking HIV PrEP in Kisumu, Kenya   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI CMR RCTP
 
31-05-2024 View

440.

ECCT/21/08/01   CARES
    Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety,and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine From Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa.   
Principal Investigator(s)
1. JOSPHAT KOSGEI
Site(s) in Kenya
1. AMPATH Eldoret (Uasin Gishu county)
2. Aghakhan University (Nairobi City county)
3. Kericho KEMRI WRP CRC site (Kericho county)
 
30-11-2021 View